Abstract：
OBJECTIVE: To investigate the status of immune checkpoint molecules (CTLA-4 and TIM-3) in meningiomas and thus contribute to the development of new personalized treatment strategies.
METHODS: We utilized 402 cases of meningioma for this study. New blocks were prepared using the tissue microarray method, and sections obtained from these blocks were immunohistochemically stained with CTLA-4 and TIM-3 antibodies. Subsequently, statistical analysis were performed.
RESULTS: Our findings revealed that CTLA-4 expression were observed in 25.1% of meningiomas. CTLA-4 expression and the number of expressing lymphocytes were found to be significantly higher in high-grade tumors and in those with brain invasion. Meningiomas with staining of immune cells with TIM-3 are 3.5%, and the tumor grade was correlated with the number of immune cells expressing TIM-3.
CONCLUSIONS: Immune checkpoint molecules (CTLA-4 and TIM-3) with varying levels of expression can serve as prognostic and predictive biomarkers, as well as important targets for therapy. Drugs developed for CTLA-4 and TIM-3 molecules may prove to be more effective in treating meningiomas with high-grade, brain-invading, spontaneous necrosis, and macronucleolus.
METHODS: We utilized 402 cases of meningioma for this study. New blocks were prepared using the tissue microarray method, and sections obtained from these blocks were immunohistochemically stained with CTLA-4 and TIM-3 antibodies. Subsequently, statistical analysis were performed.
RESULTS: Our findings revealed that CTLA-4 expression were observed in 25.1% of meningiomas. CTLA-4 expression and the number of expressing lymphocytes were found to be significantly higher in high-grade tumors and in those with brain invasion. Meningiomas with staining of immune cells with TIM-3 are 3.5%, and the tumor grade was correlated with the number of immune cells expressing TIM-3.
CONCLUSIONS: Immune checkpoint molecules (CTLA-4 and TIM-3) with varying levels of expression can serve as prognostic and predictive biomarkers, as well as important targets for therapy. Drugs developed for CTLA-4 and TIM-3 molecules may prove to be more effective in treating meningiomas with high-grade, brain-invading, spontaneous necrosis, and macronucleolus.
摘要：
目的：肿瘤全切除是治疗脑膜瘤最有效的方法。然而,缺乏有效的医疗手段，特别是对于无法手术的高级别脑膜瘤，对患者生存产生负面影响。我们旨在研究脑膜瘤中免疫检查点分子（CTLA-4和TIM-3）的状态，从而有助于开发新的个性化治疗策略。
方法：我们利用402例脑膜瘤进行本研究。使用组织微阵列方法制备新的块，和从这些块获得的切片用CTLA-4和TIM-3抗体进行免疫组织化学染色。随后，进行统计分析。
结果：我们的发现显示CTLA-4在25.1%的脑膜瘤中表达。发现CTLA-4的表达和表达淋巴细胞的数量在高级别肿瘤和脑侵袭者中明显更高。用TIM-3染色免疫细胞的脑膜瘤为3.5％，肿瘤分级与表达TIM-3的免疫细胞数量相关。
结论：不同表达水平的免疫检查点分子（CTLA-4和TIM-3）可以作为预后和预测生物标志物，以及重要的治疗靶点。为CTLA-4和TIM-3分子开发的药物可能被证明在治疗高级别脑膜瘤方面更有效，大脑入侵，自发性坏死,和大核仁。
方法：我们利用402例脑膜瘤进行本研究。使用组织微阵列方法制备新的块，和从这些块获得的切片用CTLA-4和TIM-3抗体进行免疫组织化学染色。随后，进行统计分析。
结果：我们的发现显示CTLA-4在25.1%的脑膜瘤中表达。发现CTLA-4的表达和表达淋巴细胞的数量在高级别肿瘤和脑侵袭者中明显更高。用TIM-3染色免疫细胞的脑膜瘤为3.5％，肿瘤分级与表达TIM-3的免疫细胞数量相关。
结论：不同表达水平的免疫检查点分子（CTLA-4和TIM-3）可以作为预后和预测生物标志物，以及重要的治疗靶点。为CTLA-4和TIM-3分子开发的药物可能被证明在治疗高级别脑膜瘤方面更有效，大脑入侵，自发性坏死,和大核仁。
